NCT06592326View on ClinicalTrials.gov

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

August 22, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2028

Conditions
Urothelial Carcinoma
Interventions
DRUG

9MW2821

9MW2821, 1.25mg/kg, intravenous (IV) infusion

DRUG

Toripalimab

Toripalimab, 240mg, intravenous (IV) infusion

DRUG

Gemcitabine

Gemcitabine: 1000mg/m2, intravenous (IV) infusion

DRUG

Cisplatin/Carboplatin

Cisplatin: 70mg/m2 or Carboplatin: AUC=4.5/5, intravenous (IV) infusion.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY